By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Advancing universal vaccines for flu, coronavirus, and other viral infections
Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Based on the company’s oligoDOM platform, the vaccines stimulate the immune system to produce CD-8 T cells that target the nucleoprotein (NP) produced by infected cells. The lead candidate vaccine for flu, coded OVX836, is an intramuscular form in Phase 2a development; an intranasal form is near the end of a Phase 1 trial. Preclinical studies have started on a coronavirus vaccine, which would include COVID-19. Partnerships are ongoing with an HPV prophylactic/therapeutic and a malaria vaccine in Phase 1 trials.